Organogenesis Holdings, Inc. (ORGO)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.71+4.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Broken: Primary pillar broken — Revenue reaches at least $270 million in 2026: FY26 guidance $215M vs $270M target.
Organogenesis makes wound care products. Revenue guidance is $270-$310 million in 2026. The company has stable management and a strong product base. It aims to recover from recent revenue cuts.
Revenue guidance was cut sharply from $350-$420 million to $270-$310 million. The company is still losing money. Analysts expect revenue to shrink about 25% next year.
The price is about 16% above our fair value near $2. Analysts expect revenue to fall about 25%. We see risk in meeting revenue targets.
Breaks if: Significant management disruption or failure to execute turnaround
Breaks if: EPS loss worsens beyond -$0.82 in FY26 or -$0.28 in FY27
Revenue falls below $270 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on recovering market share and improving financial performance. The current thesis state is mixed, as management is prioritizing revenue recovery but is facing significant challenges.
Valuation suggests that the market views ORGO as relatively cheap compared to its peers, with a notable expectations gap indicating that some negative outcomes may already be factored in. The current pricing reflects a justified valuation despite the company's loss-making status.
Fundamentals are likely to remain under pressure in the near term, given the elevated risk of an earnings miss and ongoing revenue declines. Management's focus on cost control and advancing product initiatives shows some promise, but results have been mixed.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company lowered its revenue guidance for 2026. This change impacts growth expectations and raises concerns about future performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The company lowered its revenue guidance for 2026 to between $270 million and $310 million.
The thesis hinges on management's ability to stabilize revenue and improve operating income while navigating potential sector momentum from larger healthcare players. Additionally, external economic factors, such as job market trends, could significantly impact performance.
In the next 1 to 3 years, ORGO's performance will depend on its execution of recovery strategies and the broader healthcare sector's health. Not investment advice.